Interferon alpha-2b/ribavirin
Alternative Names: Cotronak + interferon alpha-2b; Rebetol® + Intron A®; Rebetron; Rebetron combination therapy™; Ribavirin/interferon alpha-2bLatest Information Update: 18 Jul 2018
At a glance
- Originator Schering-Plough
- Developer Merck & Co
- Class Antivirals; Interferons; Recombinant proteins; Ribonucleosides
- Mechanism of Action Interferon alpha stimulants; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hepatitis C
Most Recent Events
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
- 25 Oct 2004 The CHMP has recommended extending the use of interferon-α-2b + ribavirin to the treatment of chronic hepatitis C in children over 3 years in the EU
- 23 Jan 2004 REBETOL® oral solution for use in combination with interferon-α-2b (INTRON® A) injection for the treatment of chronic hepatitis C in patients 3 years and older has been launched in the US